21.01.2015 Views

eur op eanexhibitionofcreati vityandinnovation - Europe Direct Iasi

eur op eanexhibitionofcreati vityandinnovation - Europe Direct Iasi

eur op eanexhibitionofcreati vityandinnovation - Europe Direct Iasi

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

EUROINVENT 2013<br />

Class no.<br />

general condition of the child's life by co-administration of two<br />

drugs: "Pacovirina" and "Capsicozida".<br />

Advantages: Consist in obtaining a method of treatment of<br />

chronic viral hepatitis C based on the synergism of two drugs:<br />

"Pacovirina" and "Capsicozida" that can be applied even if<br />

there is a high cytolysis and in children who have<br />

contraindications to the administration of antiviral therapy.<br />

4. Medicine - Health Care - Cosmetics<br />

8.57.<br />

Title<br />

Authors<br />

Institution<br />

Patent no. MD 4177<br />

Description EN<br />

Class no.<br />

METHOD OF VACCINATION AGAINST VIRAL<br />

HEPATITIS B IN IMMUNOCOMPROMISED<br />

PERSONS<br />

IG. SPÎNU, C.SPÎNU, O SAJEN, M.ISAC, V.GURIEV,<br />

P. CHINTEA, V PÂNTEA<br />

National Center for Public Health<br />

Republic of Moldova<br />

Aim: Enhancing the effectiveness of immunization against<br />

HBV in pe<strong>op</strong>le with compromised immune status especially in<br />

pregnant women and pe<strong>op</strong>le from group with high risk of HBV<br />

infection and the reduction of the number non-responders to<br />

the vaccine by co-administration of vaccine against HBV and<br />

an vegetable adaptogen - Mestim, which manifests mainly<br />

stimulating immunogenesis process.<br />

Solution: Intensification of immunogenesis expressed by a<br />

significant titers of protective antibody, resulting in<br />

minimizing the risk of HBV cases in pe<strong>op</strong>le with compromised<br />

immune status including pregnant women and the reduction of<br />

the number of non-responders to the vaccine.<br />

Advantages: Mestim is of plant origin free of cumulative,<br />

toxic, action, teratogenic, rezorptive, carcinogenic action,<br />

medicinal product do not devel<strong>op</strong> side effects and is easily<br />

tolerated by patients.<br />

4. Medicine - Health Care - Cosmetics<br />

8.58.<br />

Title<br />

Authors<br />

Institution<br />

Patent no.<br />

METHOD OF CHILDREN REVACCINATION<br />

AGAINST HEPATITIS B<br />

O. SAJEN, V.GURIEV, C. SPÎNU, I. SPÎNU, V.<br />

PÂNTEA<br />

National Center for Public Health<br />

Republic of Moldova<br />

MD 223 Y<br />

INTERNATIONAL EXHIBITS<br />

104

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!